Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

4.1K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
4.1K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.4K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.4K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

1.3K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.3K
Pericarditis IV: Nursing Management01:25

Pericarditis IV: Nursing Management

588
Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
588

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variability in Recommendations for Measles, Mumps, Rubella Vaccination and Vitamin A Administration in the Setting of Measles Outbreaks.

Journal of the Pediatric Infectious Diseases Society·2026
Same author

Fluid sparing effects of chemokine (C-C motif) receptor 1 and 2 antagonists during resuscitation from hemorrhagic shock in rat models.

PloS one·2026
Same author

Clinical and economic burden of recurrence among older patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Journal of managed care & specialty pharmacy·2026
Same author

A collaborative approach to applying Natural Language Processing (NLP) to Domestic Homicide Reviews (DHRs): A study protocol.

PloS one·2026
Same author

Randomized Controlled Trials Comparing the Standard of Care to Alternative Treatments in Patients with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Systematic Literature Review.

Advances in therapy·2026
Same author

Frequency and Duration of Diagnostic Delays Associated with Coccidioidomycosis and Risk Factors for Missed Diagnoses, United States.

Emerging infectious diseases·2026

Related Experiment Video

Updated: Apr 16, 2026

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.6K

Increased statin prescribing does not lower pneumonia risk.

Linnea A Polgreen1, Elizabeth A Cook2, John M Brooks3

  • 1Department of Pharmacy Practice and Science.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|March 12, 2015
PubMed
Summary

Statins may not protect against pneumonia in acute myocardial infarction patients. Initial observational data suggested a benefit, but instrumental variable analysis revealed this was likely due to healthy user bias, not a direct effect.

Keywords:
geographic treatment ratesinstrumental variablespneumoniastatin

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.6K
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

743

Related Experiment Videos

Last Updated: Apr 16, 2026

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.6K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.6K
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

743

Area of Science:

  • Cardiovascular Medicine
  • Infectious Disease Epidemiology
  • Pharmacoepidemiology

Background:

  • Previous observational studies suggested statins offer protection against pneumonia.
  • Concerns exist regarding confounding by indication and healthy-user bias in these prior reports.
  • The non-randomized nature of observational data limits causal inference regarding statin use and pneumonia risk.

Purpose of the Study:

  • To investigate whether the observed protective effect of statins against pneumonia is attributable to nonrandom treatment assignment.
  • To differentiate between a true pharmacological effect and confounding factors in the statin-pneumonia association.

Main Methods:

  • A cohort of 124,695 Medicare beneficiaries with acute myocardial infarction (AMI) was analyzed.
  • Ordinary least squares (OLS) and logistic regression models were used initially.
  • Instrumental variable analysis, using geographic treatment rates, controlled for nonrandom assignment.
  • Pneumonia diagnosis within one year post-AMI served as the primary outcome.

Main Results:

  • OLS models indicated a statistically significant association between statin use and reduced pneumonia risk (coefficient -0.016, P < .001).
  • However, instrumental variable analysis demonstrated no significant association between statin prescriptions and pneumonia.
  • Statin coefficients in IV models ranged from -0.001 to -0.01 (P > .6), indicating no protective effect after accounting for confounding.

Conclusions:

  • The apparent protective effect of statins against pneumonia in AMI patients is likely a result of nonrandom treatment assignment.
  • Healthy-user bias, where patients who take statins are inherently healthier, explains the observed association.
  • Statins do not appear to have a direct protective effect against pneumonia in this population.